LOVE — Cannara Biotech Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual cashflow statement for Cannara Biotech, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.

	2020 August 31st	2021 August 31st	2022 August 31st	C2023 August 31st	2024 August 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-13.1	-1.53	2.31	6.95	6.44
Depreciation
Amortisation
Non-Cash Items	1.48	0.229	-0.822	-0.337	0.39
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-0.29	-3.82	-11.5	-5.64	-2.5
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-9.32	-2.09	-6.08	5.91	10.7
Capital Expenditures	-9.18	-30.6	-15.1	-9.31	-7.07
Purchase of Fixed Assets
Other Investing Cash Flow Items	0.631	-0.223	-0.25	-0.166	1.88
Sale of Fixed Assets
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities	-8.55	-30.8	-15.3	-9.48	-5.19
Financing Cash Flow Items	-1.13	-1.49	-1.61	-4.63	-3.9
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-0.915	33.3	25.5	-4.19	-3.14
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-18.7	0.388	3.96	-7.84	2.35